Establishment Labs Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance

Establishment Labs reported third-quarter 2026 revenue of $72.0 million, up 33.9% year over year, and a GAAP net loss of $10.7 million, or $0.35 per share, compared with a $11.1 million loss a year earlier. Adjusted EBITDA rose to $6.4 million, or 8.9% of revenue, from $1.2 million, or 2.2%. The company raised its 2026 revenue guidance to $269 million–$271 million, received FDA approval for additional smaller Motiva implant sizes, and recorded its first quarter of positive operating cash flow.